Company updateBusinessLine
Biocon gets European Commission nod for breast cancer biosimilar
Positive+402 sources
GreyOak summary
Biocon received European Commission approval for Pebrilzo, a biosimilar version of pertuzumab, to treat HER2-positive breast cancer. This marks the fifth oncology biosimilar approved by the company in both Europe and the US. The drug is indicated for neoadjuvant and adjuvant treatment of adults with high-risk early breast cancer.
What it affects
- BioconBIOCONPositive +40
Received EU approval for breast cancer biosimilar.Rolling sentiment Positive +23
Source
Read the original at BusinessLineMore Biocon news
- Biocon's Pebrilzo gets first EMA tailored pathway approvalBusinessLine · Company update ·
- Biocon gets EU nod for Pebrilzo breast cancer drugBusiness Standard · Company update ·